Literature DB >> 1801548

Human leukocyte antigens in childhood idiopathic nephrotic syndrome.

D K Jin1, T Kohsaka, M Tanaka, J Abe, N Kobayashi.   

Abstract

An association of human leukocyte antigens (HLA) with idiopathic nephrotic syndrome (INS) in childhood was studied to characterize the immunogenetic background. We determined the class I antigens using the microlymphocytotoxicity test as well as class II antigens (DRB, DQB, DQA) and class III antigen (complement 4) using DNA restriction fragment length polymorphism (RFLP) in 36 children with INS. In the current study, neither the single allele in HLA class I antigen nor the single gene frequency in the class II region was significantly increased, in contrast to the results in Caucasian INS patients in whom a genetic predisposition to the HLA system, especially to HLA B8, DR3, and DR7, has been frequently reported. Also, in our data, the frequency of deletion of complement 4 gene was not different from that of the controls. These data suggest that there is a difference in immunogenetic background between Caucasian and Japanese INS patients as far as HLA is concerned.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801548     DOI: 10.1111/j.1442-200x.1991.tb02595.x

Source DB:  PubMed          Journal:  Acta Paediatr Jpn        ISSN: 0374-5600


  2 in total

1.  High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study).

Authors:  Kaori Kikunaga; Kenji Ishikura; Chikako Terano; Mai Sato; Fumiyo Komaki; Yuko Hamasaki; Satoshi Sasaki; Kazumoto Iijima; Norishige Yoshikawa; Koichi Nakanishi; Hitoshi Nakazato; Takeshi Matsuyama; Takashi Ando; Shuichi Ito; Masataka Honda
Journal:  Clin Exp Nephrol       Date:  2016-09-02       Impact factor: 2.801

2.  The polymorphism of the immunoglobulin heavy chain switch region gene in IgA nephropathy, Henoch-Schönlein nephritis and idiopathic nephrotic syndrome.

Authors:  D K Jin; T Kohsaka; N Kobayashi
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.